{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:27:07Z","timestamp":1778588827886,"version":"3.51.4"},"reference-count":50,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,12,15]]},"DOI":"10.2169\/internalmedicine.2551-23","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T22:55:37Z","timestamp":1697151337000},"page":"3699-3706","source":"Crossref","is-referenced-by-count":6,"title":["New-onset Immune-mediated Necrotizing Myopathy and Trigeminal Neuropathy after SARS-CoV-2 mRNA Vaccination in a Patient with Rheumatoid Arthritis and Sj\u00f6gren's Syndrome"],"prefix":"10.2169","volume":"62","author":[{"given":"Takuma","family":"Tsuzuki Wada","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yokota","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumito","family":"Inayoshi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakon","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhito","family":"Okumura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iichiro","family":"Osawa","sequence":"additional","affiliation":[{"name":"Department of Radiology, Saitama Medical University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuto","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Funakubo Asanuma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihide","family":"Mimura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383: 2603-2615, 2020.","DOI":"10.1056\/NEJMoa2034577"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384: 403-416, 2021.","DOI":"10.1056\/NEJMoa2035389"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 326: 1390-1399, 2021.","DOI":"10.1001\/jama.2021.15072"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Velikova T, Georgiev T. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol Int 41: 509-518, 2021.","DOI":"10.1007\/s00296-021-04792-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 80: 1330-1338, 2021.","DOI":"10.1136\/annrheumdis-2021-220647"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Furer V, Eviatar T, Zisman D, et al. Predictors of immunogenic response to the BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases treated with rituximab. Vaccines (Basel) 10: 901, 2022.","DOI":"10.3390\/vaccines10060901"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Matsuda M, Funakubo Asanuma YF, Yokota K, et al. New-onset adult-onset Still&apos;s disease following COVID-19 vaccination: three case reports and a literature review. Intern Med 62: 299-305, 2023.","DOI":"10.2169\/internalmedicine.0590-22"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol 16: 689-701, 2020.","DOI":"10.1038\/s41584-020-00515-9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Albayda J, Khan A, Casciola-Rosen L, Corse AM, Paik JJ, Christopher-Stine L. Inflammatory myopathy associated with anti-mitochondrial antibodies: a distinct phenotype with cardiac involvement. Semin Arthritis Rheum 47: 552-556, 2018.","DOI":"10.1016\/j.semarthrit.2017.06.004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Zhang L, Yang H, Lei J, et al. Muscle pathological features and extra-muscle involvement in idiopathic inflammatory myopathies with anti-mitochondrial antibody. Semin Arthritis Rheum 51: 741-748, 2021.","DOI":"10.1016\/j.semarthrit.2021.05.019"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Li JC, Siglin J, Marshall MS, Stemmer-Rachamimov A, Bloom SM, Blumenthal KG. Successful treatment of delayed localized necrotizing inflammatory myositis after severe acute respiratory syndrome coronavirus 2 mRNA-1273 vaccine: a case report. Open Forum Infect Dis 9: ofac499, 2022.","DOI":"10.1093\/ofid\/ofac499"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Chang CH, Gupta R, Setyono D, Cuevas-Ocampo AK, Khoshnoodi MA. Refractory seronegative immune-mediated necrotizing myopathy after receiving mRNA-1273 SARS-CoV-2 vaccine: a case report. J Clin Neuromuscul Dis 24: 168-169, 2023.","DOI":"10.1097\/CND.0000000000000431"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Dodig D, Fritzler MJ, Naraghi A, Tarnopolsky MA, Lu JQ. Immune-mediated necrotizing myopathy after BNT162b2 vaccination in a patient with antibodies against receptor-binding domain of SARS-CoV-2 and signal recognition particle. Muscle Nerve 65: E11-E13, 2022.","DOI":"10.1002\/mus.27483"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Durucan I, Guner S, Kilickiran Avci BK, Unverengil G, Melikoglu M, Ugurlu S. Post-COVID-19 vaccination inflammatory syndrome: a case report. Mod Rheumatol Case Rep 7: 280-282, 2023.","DOI":"10.1093\/mrcr\/rxac041"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Blaise M, Rocher F, Spittler H, et al. Severe necrotizing myopathy after COVID-19 vaccine with BNT162b2 and regimen with ipilimumab plus nivolumab in a patient with advanced melanoma. J Eur Acad Dermatol Venereol 36: e100-e102, 2022.","DOI":"10.1111\/jdv.17760"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Tanemoto M, Oda R, Toyama Y, et al. Anti-signal recognition particle antibody-positive immune-mediated myopathy after mRNA-1273 SARS-CoV-2 vaccination. Intern Med 61: 3605-3609, 2022.","DOI":"10.2169\/internalmedicine.0404-22"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mufti Z, Dietz N, Pearson L, et al. Immune-mediated necrotizing myopathy with concurrent statin use after routine COVID-19 inoculation: a case report. Cureus 15: e37876, 2023.","DOI":"10.7759\/cureus.37876"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kanduc D, Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. Immunol Res 68: 310-313, 2020.","DOI":"10.1007\/s12026-020-09152-6"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J Transl Autoimmun 3: 100051, 2020.","DOI":"10.1016\/j.jtauto.2020.100051"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol 11: 617089, 2020.","DOI":"10.3389\/fimmu.2020.617089"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Suh J, Mukerji SS, Collens SI, et al. Skeletal muscle and peripheral nerve histopathology in COVID-19. Neurology 97: e849-e858, 2021.","DOI":"10.1212\/WNL.0000000000012344"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Aschman T, Schneider J, Greuel S, et al. Association between SARS-CoV-2 infection and immune-mediated myopathy in patients who have died. JAMA Neurol 78: 948-960, 2021.","DOI":"10.1001\/jamaneurol.2021.2004"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Talotta R. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to &quot;potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases&quot; . Clin Immunol 224: 108665, 2021.","DOI":"10.1016\/j.clim.2021.108665"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Saud A, Naveen R, Aggarwal R, Gupta L. COVID-19 and myositis: what we know so far. Curr Rheumatol Rep 23: 63, 2021.","DOI":"10.1007\/s11926-021-01023-9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Lin F, Lin X, Fu B, Xiong Y, Zaky MY, Wu H. Functional studies of HLA and its role in SARS-CoV-2: stimulating T cell response and vaccine development. Life Sci 315: 121374, 2023.","DOI":"10.1016\/j.lfs.2023.121374"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Talotta R. Molecular mimicry and HLA polymorphisms may drive autoimmunity in recipients of the BNT-162b2 mRNA vaccine: a computational analysis. Microorganisms 11: 1686, 2023.","DOI":"10.3390\/microorganisms11071686"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, Anaya JM. HLA and Sj\u00f6gren&apos;s syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev 11: 281-287, 2012.","DOI":"10.1016\/j.autrev.2011.10.002"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Saepoo J, Pangsomboon K, Tianviwat S. Awareness of HLA-B* 15:02 screening in trigeminal neuralgia and the gene screening policy among dentists in Southern Thailand. Spec Care Dentist 43: 286-293, 2023.","DOI":"10.1111\/scd.12768"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ohnuki Y, Suzuki S, Uruha A, et al. Association of immune-mediated necrotizing myopathy with HLA polymorphisms. HLA 101: 449-457, 2023.","DOI":"10.1111\/tan.14950"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kang EH, Go DJ, Mimori T, et al. Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients. Semin Arthritis Rheum 49: 283-287, 2019.","DOI":"10.1016\/j.semarthrit.2019.03.005"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Bergua C, Chiavelli H, Allenbach Y, et al. <i>In vivo<\/i> pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis 78: 131-139, 2019.","DOI":"10.1136\/annrheumdis-2018-213518"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol 16: 689-701, 2020.","DOI":"10.1038\/s41584-020-00515-9"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Shimada T, Higashida-Konishi M, Akiyama M, et al. Immune-mediated necrotizing myopathy which showed deposition of C5b-9 in the necrotic muscle fibers and was successfully treated with intensive combined therapy with high-dose glucocorticoids, tacrolimus, and intravenous immunoglobulins. Immunol Med 45: 175-179, 2022.","DOI":"10.1080\/25785826.2022.2060169"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Chavarr\u00eda-Miranda A, Hern\u00e1ndez Lain A, Toldos Gonz\u00e1lez O, Pedraza Hueso MI. Immune-mediated necrotising myopathy after treatment with adalimumab in a patient with HLA-B27 ankylosing spondylitis. Neurologia (Engl Ed) 36: 631-632, 2021.","DOI":"10.1016\/j.nrleng.2021.06.001"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Eriksson C, Engstrand S, Sundqvist KG, Rantap\u00e4\u00e4-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 64: 403-407, 2005.","DOI":"10.1136\/ard.2004.024182"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Ramos-Casals M, Brito-Zer\u00f3n P, Mu\u00f1oz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86: 242-251, 2007.","DOI":"10.1097\/MD.0b013e3181441a68"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Singh VK, Mehrotra S, Agarwal SS. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 20: 147-161, 1999.","DOI":"10.1007\/BF02786470"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38. Lorenz HM, Herrmann M, Winkler T, Gaipl U, Kalden JR. Role of apoptosis in autoimmunity. Apoptosis 5: 443-449, 2000.","DOI":"10.1023\/A:1009692902805"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Kaya A, Kaya SY. A case of trigeminal neuralgia developing after a COVID-19 vaccination. J Neurovirol 28: 181-182, 2022.","DOI":"10.1007\/s13365-021-01030-7"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Onoda K, Sashida R, Fujiwara R, et al. Trigeminal neuropathy after tozinameran vaccination against COVID-19 in postmicrovascular decompression for trigeminal neuralgia: illustrative case. J Neurosurg Case Lessons 3: CASE22101, 2022.","DOI":"10.3171\/CASE22101"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Lee S, Hor JY, Koh KL, Chia YK. Central nervous system demyelination following COVID-19 mRNA-based vaccination: two case reports and literature review. J Cent Nerv Syst Dis 14: 11795735221102747, 2022.","DOI":"10.1177\/11795735221102747"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Khayat-Khoei M, Bhattacharyya S, Katz J, et al. COVID-19 mRNA vaccination leading to CNS inflammation: a case series. J Neurol 269: 1093-1106, 2022.","DOI":"10.1007\/s00415-021-10780-7"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Havla J, Schultz Y, Zimmermann H, Hohlfeld R, Danek A, K\u00fcmpfel T. First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine. J Neurol 269: 55-58, 2022.","DOI":"10.1007\/s00415-021-10648-w"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44: 2862-2869, 2001.","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Kumar N, Abboud H. Iatrogenic CNS demyelination in the era of modern biologics. Mult Scler 25: 1079-1085, 2019.","DOI":"10.1177\/1352458519828601"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Gono T, Kawaguchi Y, Katsumata Y, et al. Clinical manifestations of neurological involvement in primary Sj\u00f6gren&apos;s syndrome. Clin Rheumatol 30: 485-490, 2011.","DOI":"10.1007\/s10067-010-1458-7"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Horai Y, Nishino A, Nakashima Y, et al. Case of Sj\u00f6gren&apos;s syndrome presenting as trigeminal nerve palsy. Nihon Rinsho Meneki Gakkai Kaishi 35: 199-202, 2012.","DOI":"10.2177\/jsci.35.199"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Farran MZ, Kesserwani H. A case of Sj\u00f6gren&apos;s syndrome associated with trigeminal neuropathy and enhancement of the mandibular nerve at the foramen ovale: a case report and a review of the differential diagnosis and mechanisms of the disease. Cureus 13: e19463, 2021.","DOI":"10.7759\/cureus.19463"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Narasimhalu K, Lee WC, Salkade PR, De Silva DA. Trigeminal and cervical radiculitis after tozinameran vaccination against COVID-19. BMJ Case Rep 14: e242344, 2021.","DOI":"10.1136\/bcr-2021-242344"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Panagiotides NG, Zimprich F, Machold K, et al. A case of autoimmune small fiber neuropathy as possible post COVID sequelae. Int J Environ Res Public Health 20: 4918, 2023.","DOI":"10.3390\/ijerph20064918"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/24\/62_2551-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T03:22:15Z","timestamp":1702696935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/24\/62_2551-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":50,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2551-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"article-number":"2551-23"}}